Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review
Open Access
- 1 June 2005
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (11), 3974-3986
- https://doi.org/10.1158/1078-0432.ccr-04-2661
Abstract
Lung cancer is the leading cause of cancer death in the U.S. with survival restricted to a subset of those patients able to undergo surgical resection. However, even with surgery, recurrence rates range from 30% to 60%, depending on the pathologic stage. With the advent of partially effective, but potentially toxic adjuvant chemotherapy, it has become increasingly important to discover biomarkers that will identify those patients who have the highest likelihood of recurrence and who thus might benefit most from adjuvant chemotherapy. Hundreds of papers have appeared over the past several decades proposing a variety of molecular markers or proteins that may have prognostic significance in non–small cell lung cancer. This review analyzes the largest and most rigorous of these studies with the aim of compiling the most important prognostic markers in early stage non–small cell lung cancer. In this review, we focused on biomarkers primarily involved in one of three major pathways: cell cycle regulation, apoptosis, and angiogenesis. Although no single marker has yet been shown to be perfect in predicting patient outcome, a profile based on the best of these markers may prove useful in directing patient therapy. The markers with the strongest evidence as independent predictors of patient outcome include cyclin E, cyclin B1, p21, p27, p16, survivin, collagen XVIII, and vascular endothelial cell growth factor.Keywords
This publication has 84 references indexed in Scilit:
- Clinical significance of P16INK4A and retinoblastoma proteins in non-small-cell lung carcinomaLung Cancer, 2002
- Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomasThe Journal of Pathology, 2002
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- c-MET Expression in MyofibroblastsThe American Journal of Pathology, 2001
- Vascular Endothelial Growth Factor Expression in Stage I Non-Small Cell Lung Cancer Correlates With Neoangiogenesis and a Poor PrognosisAnnals of Surgical Oncology, 2001
- Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patientsEuropean Journal Of Cancer, 1999
- Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinomaOncogene, 1999
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markersEuropean Journal Of Cancer, 1996
- The Effect of Surgical Treatment on Survival from Early Lung Cancer: Implications for ScreeningChest, 1992